Getting Pregnant on Ozempic: What to Do in the First 24 Hours and Beyond

Trust signals

> Reviewed by FormBlends Medical Team · Last updated May 2026 · 12 sources cited

Key Takeaways

• Stop the medication. Do not take additional doses while awaiting clinician contact.
• Book an OB-GYN visit promptly. Most prescribers also want a call so they can adjust diabetes or obesity care planning.
• Start prenatal vitamins with at least 400 mcg of folic acid if not already taking them.
• First-trimester semaglutide exposure has not shown a specific malformation pattern in available human data, but the data are limited.
• Consider enrolling in the manufacturer pregnancy exposure registry to contribute to future evidence.

Direct answer

If you find out you are pregnant on Ozempic, stop the medication, contact your prescriber within the day, and schedule an obstetric appointment within the week. Begin prenatal vitamins. Plan for a dating ultrasound and a glycemic or weight-management plan that does not include GLP-1 medications during pregnancy. Pregnancy on GLP-1 medications is a clinical situation that warrants OB-GYN sign-off before any change in regimen; do not start, continue, or stop these medications in isolation.

Table of contents

1. The first 24 hours
2. The first week
3. The first trimester
4. Fetal exposure framing for counseling
5. The pharmacokinetics of clearance
6. If you have type 2 diabetes
7. If you were taking semaglutide for obesity
8. Pregnancy registries and how to enroll
9. Monitoring through the rest of pregnancy
10. Postpartum considerations and breastfeeding
11. FAQ
12. Sources

The first 24 hours

The single most important action is to stop the medication. Skip the upcoming dose if you have a positive home pregnancy test. Confirm pregnancy with your clinician using a quantitative HCG if appropriate, but do not delay discontinuation while awaiting confirmation.

Call your prescriber's office. Many practices have an after-hours line; this is an appropriate reason to use it. The conversation should cover discontinuation, glucose plan if you have diabetes, and an obstetric referral pathway.

Start a prenatal vitamin today. Most pregnancies benefit from at least 400 mcg of folic acid daily; some indications call for higher doses (history of neural tube defect, certain anticonvulsants, etc.). If you have not already chosen a prenatal vitamin, a standard over-the-counter formulation works for the interim.

The first week

Schedule the obstetric appointment. If you have an existing OB-GYN, ask for the earliest available pregnancy intake visit. If you do not, prioritize finding one and asking for a same-week intake.

Order or schedule baseline labs if your obstetric provider has not already. Standard pregnancy intake includes blood type and antibody screen, complete blood count, infectious disease screening, and urine. If you have diabetes, add A1c.

Sort out the medication transition. For diabetes patients, this often means insulin titration during the gap. For obesity-indication patients, no replacement medication is added during pregnancy; weight management shifts to appropriate gestational weight gain rather than weight loss.

The first trimester

Most first-trimester care follows standard pregnancy protocols. Dating ultrasound, intake history and physical, first-trimester aneuploidy screening if elected. Add a discussion with your obstetric team about your exposure history. Some practices route patients with first-trimester medication exposure to maternal-fetal medicine for a one-time counseling visit.

Track symptoms. Nausea in early pregnancy is common (50 to 90 percent of pregnancies). After stopping semaglutide, some patients describe their pregnancy nausea as different from the medication nausea they had previously experienced. This is mostly a comfort note; symptom patterns do not predict outcomes in any specific way here.

Fetal exposure framing for counseling

The honest framing for counseling is that the absolute risk increase from first-trimester semaglutide exposure, if any exists, appears modest in available human data. The animal data raised concerns at clinically relevant exposures, which is why the FDA label directs discontinuation. The human data we have, mostly from case series and a manufacturer registry, have not identified a specific malformation pattern.

The numbers most relevant for counseling:

• Background risk of major congenital anomaly in the general population: approximately 3 to 5 percent of live births.
• Background risk of pregnancy loss before 20 weeks: approximately 10 to 20 percent of recognized pregnancies.
• Total reported semaglutide pregnancy exposures: still in the low thousands across published sources, with most exposures occurring before pregnancy recognition.

The size of the human dataset is the binding constraint. Even if the true relative risk is small, detecting it requires more exposures than have been reported.

The pharmacokinetics of clearance

Semaglutide has a half-life of approximately 1 week. The drug is largely cleared in about 5 weeks. Practical implications:

• By the time most patients recognize pregnancy (4 to 6 weeks of gestation), the embryo has been exposed during weeks 3 to 4. Organogenesis spans weeks 3 to 8.
• Stopping at week 5 of gestation does not eliminate first-trimester exposure. It only ends future exposure.
• By approximately the start of the second trimester, semaglutide should be undetectable in most patients regardless of when discontinuation occurred in the first trimester.

This timeline is why the pre-pregnancy washout recommendation (stop at least 2 months before conception) exists. It is also why inadvertent exposure is so common; the time between conception and pregnancy recognition is exactly the period when the medication is acting on the early embryo.

If you have type 2 diabetes

Diabetes care in pregnancy is its own specialty. Key adjustments:

• Glycemic targets tighten. The American Diabetes Association recommends fasting glucose less than 95 mg/dL and 1-hour postprandial less than 140 mg/dL or 2-hour less than 120 mg/dL in pregnancy.
• Insulin becomes the preferred agent. Multiple regimens accommodate different lifestyles; pumps are an option.
• Metformin is used in some settings as monotherapy or as an adjunct.
• A1c monitoring continues, but real-time glucose monitoring (continuous glucose monitoring) is often added.
• Pregnancy-specific diabetes care often involves both an endocrinologist and an obstetrician working together.

If you were taking semaglutide for obesity

Weight loss is not a goal during pregnancy. The goal is appropriate gestational weight gain based on starting BMI, per the Institute of Medicine guidance:

Pre-pregnancy BMI	Total weight gain (singleton)
Underweight (less than 18.5)	28 to 40 lb
Normal weight (18.5 to 24.9)	25 to 35 lb
Overweight (25 to 29.9)	15 to 25 lb
Obesity (30 and above)	11 to 20 lb

Obesity-related conditions deserve targeted attention: blood pressure monitoring, sleep apnea screening, gestational diabetes screening, and venous thromboembolism risk assessment. These are part of routine high-risk obstetric care.

Pregnancy registries and how to enroll

Novo Nordisk runs a semaglutide pregnancy exposure registry. Enrollment is voluntary and confidential. Your prescriber can initiate the referral, or you can call the manufacturer medical information line directly.

Why enroll? Because the binding constraint on the evidence base is the small number of reported exposures. Each enrollment contributes information that will help future patients face this same situation with better data.

Monitoring through the rest of pregnancy

Beyond the standard obstetric schedule, common additions in this scenario:

• Detailed anatomy ultrasound around 18 to 22 weeks.
• Glucose tolerance test at 24 to 28 weeks for gestational diabetes screening, even if not previously diabetic.
• Growth ultrasounds in the third trimester for patients with diabetes or obesity.
• Antenatal testing (nonstress test or biophysical profile) as indicated.

Postpartum considerations and breastfeeding

After delivery, the question of restarting semaglutide reopens. The current LactMed guidance recommends against use during breastfeeding until more data are available. Patients who plan to breastfeed exclusively typically defer restart. Patients who are not breastfeeding or who have weaned can resume after discussion with their prescriber.

Postpartum weight retention is a known issue. Most clinicians recommend gradual, lactation-compatible weight loss through nutrition and activity during breastfeeding, with medication options reconsidered once feeding has transitioned.

FAQ

What do I do if I find out I am pregnant while on Ozempic?

Stop the medication, call your prescriber, book an OB-GYN visit, and begin a prenatal vitamin. Do not start, continue, or stop GLP-1 medications without OB-GYN sign-off.

Is fetal exposure during early pregnancy dangerous?

Animal data showed risk; human data are limited but have not identified a specific malformation pattern. Counseling should acknowledge uncertainty without overstatement.

How long until Ozempic is out of my system?

Approximately 5 weeks.

Should I get an early ultrasound?

Yes, for dating and reassurance. A second-trimester anatomy ultrasound is standard.

Should I report this to a pregnancy registry?

Yes if you are comfortable. The Novo Nordisk registry collects voluntary data.

Can I take a small dose to taper rather than stop suddenly?

No taper is needed. Stop cleanly.

What about miscarriage risk?

Animal embryofetal loss was documented at high doses. Human evidence is inconclusive, complicated by the general background rate.

Do I need any special prenatal screening?

Standard plus possibly maternal-fetal medicine consultation for counseling.

How will my weight and appetite change after stopping?

Appetite typically returns within weeks. Pregnancy weight gain follows the IOM ranges based on starting BMI.

What if I have diabetes and need glycemic control?

Transition to insulin or another pregnancy-appropriate regimen, with tighter glycemic targets and closer follow-up.

Related guides

• Can You Take Ozempic While Pregnant? What the FDA Label, Animal Studies, and ACOG Actually Say
• Can You Get Pregnant on Ozempic? Fertility, PCOS, and What Patients Often Underestimate
• What Happens If You Get Pregnant on Ozempic? The Clinical Pathway From Discovery to Delivery

Sources

1. FDA. Ozempic (semaglutide) injection prescribing information. Use in Specific Populations.
2. American College of Obstetricians and Gynecologists. Practice Bulletin 230: Obesity in Pregnancy. 2021.
3. American Diabetes Association. Standards of Care in Diabetes: Management of Diabetes in Pregnancy.
4. Institute of Medicine. Weight Gain During Pregnancy: Reexamining the Guidelines. 2009.
5. Society for Maternal-Fetal Medicine. Consult Series on Obesity in Pregnancy.
6. National Library of Medicine. LactMed. Semaglutide entry.
7. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
8. Novo Nordisk. Semaglutide Pregnancy Exposure Registry. Manufacturer-sponsored pharmacovigilance.
9. European Medicines Agency. Ozempic Summary of Product Characteristics. Section 4.6.
10. Apovian CM et al. Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline. JCEM. 2015 with subsequent updates.
11. Briggs Drugs in Pregnancy and Lactation. Most recent edition.
12. ACOG Committee Opinion 731: Obesity in Pregnancy. 2018, reaffirmed.

Footer disclaimers

Platform Disclaimer. FormBlends links patients with independent licensed clinicians and U.S.-based pharmacies. We do not provide direct medical care, write prescriptions, or dispense medication. Pregnancy decisions belong to you and the clinicians caring for you.

Compounded Medication Notice. Compounded semaglutide is not FDA-approved. It is prepared by a state-licensed 503A pharmacy. Pregnancy warnings that apply to FDA-approved semaglutide apply with at least equal weight to compounded versions.

Results Disclaimer. This article describes general clinical considerations after pregnancy is discovered on semaglutide. It is not a personalized care plan. Your obstetric provider will tailor monitoring and management to your specific situation.

Trademark Notice. Ozempic is a registered trademark of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk.